Elanco Animal Health Inc ELAN
We take great care to ensure that the data presented and summarized in this overview for Elanco Animal Health Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELAN
View all-
Dodge & Cox San Francisco, CA83.3MShares$1.11 Billion0.74% of portfolio
-
Primecap Management CO Pasadena, CA52.6MShares$700 Million0.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA48.9MShares$651 Million0.01% of portfolio
-
Black Rock Inc. New York, NY23.3MShares$310 Million0.01% of portfolio
-
Black Creek Investment Management Inc. Toronto, A621.3MShares$284 Million11.09% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD21MShares$280 Million0.19% of portfolio
-
Dimensional Fund Advisors LP Austin, TX16.8MShares$224 Million0.06% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL12.6MShares$168 Million0.05% of portfolio
-
Shapiro Capital Management LLC Atlanta, GA11.5MShares$153 Million5.4% of portfolio
-
Magnetar Financial LLC Evanston, IL10.6MShares$141 Million4.52% of portfolio
Latest Institutional Activity in ELAN
Top Purchases
Top Sells
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Insider Transactions at ELAN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 22
2024
|
Michael J Harrington |
BUY
Open market or private purchase
|
Direct |
3,500
+4.14%
|
$49,000
$14.85 P/Share
|
Aug 12
2024
|
Jeffrey N Simmons PRESIDENT, CEO AND DIRECTOR |
BUY
Open market or private purchase
|
Indirect |
100,000
+40.82%
|
$1,300,000
$13.01 P/Share
|
Jul 03
2024
|
Grace Mc Ardle EVP, MANUFACTURING AND QUALITY |
SELL
Payment of exercise price or tax liability
|
Direct |
4,345
-7.91%
|
$60,830
$14.13 P/Share
|
Jul 03
2024
|
James M Meer CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,160
-2.3%
|
$16,240
$14.13 P/Share
|
May 21
2024
|
William F Doyle |
BUY
Open market or private purchase
|
Direct |
15,000
+16.42%
|
$240,000
$16.98 P/Share
|
Apr 03
2024
|
Timothy J Bettington |
SELL
Payment of exercise price or tax liability
|
Direct |
23,557
-18.13%
|
$353,355
$15.43 P/Share
|
Apr 01
2024
|
Rajeev A. Modi |
SELL
Payment of exercise price or tax liability
|
Direct |
7,509
-9.72%
|
$112,635
$15.97 P/Share
|
Mar 08
2024
|
Michael J Harrington |
BUY
Open market or private purchase
|
Direct |
3,100
+3.84%
|
$49,600
$16.29 P/Share
|
Mar 08
2024
|
William F Doyle |
BUY
Open market or private purchase
|
Direct |
15,000
+19.65%
|
$240,000
$16.3 P/Share
|
Mar 06
2024
|
R David Hoover |
BUY
Open market or private purchase
|
Indirect |
20,000
+9.76%
|
$320,000
$16.14 P/Share
|
Mar 05
2024
|
Jeffrey N Simmons PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
11,012
-0.81%
|
$165,180
$15.99 P/Share
|
Mar 05
2024
|
Todd S. Young |
BUY
Bona fide gift
|
Indirect |
3,000
+30.0%
|
-
|
Mar 05
2024
|
Todd S. Young |
SELL
Bona fide gift
|
Indirect |
3,000
-0.99%
|
-
|
Mar 05
2024
|
Todd S. Young |
BUY
Bona fide gift
|
Indirect |
37,999
+19.97%
|
-
|
Mar 05
2024
|
Todd S. Young |
SELL
Bona fide gift
|
Direct |
37,999
-27.5%
|
-
|
Mar 01
2024
|
Timothy J Bettington |
BUY
Grant, award, or other acquisition
|
Direct |
21,835
+14.39%
|
-
|
Mar 01
2024
|
Shiv O'Neill GC AND CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,354
-5.39%
|
$21,664
$16.03 P/Share
|
Mar 01
2024
|
Shiv O'Neill GC AND CORP SEC |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+38.3%
|
-
|
Mar 01
2024
|
James M Meer CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,667
-3.2%
|
$26,672
$16.03 P/Share
|
Mar 01
2024
|
James M Meer CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,046
+14.81%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 881K shares |
---|---|
Open market or private purchase | 157K shares |
Bona fide gift | 41K shares |
Payment of exercise price or tax liability | 263K shares |
---|---|
Bona fide gift | 41K shares |